• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Predictions for 2/22 BUSINEES UPDATE


<











hearing our patients is great, but I think they put these two ladies up just to divert us from the real issues we are facing.
Other than that, just the usual speech: our pipeline is great, our people are great, our results are great. They should bring Tony the tiger for the next meeting and just have him saying it’s grrrrrrreat.
House of cards!
 








Similar threads